Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

PHARMACIE DE MONTUSSAN : revenue, balance sheet and financial ratios

PHARMACIE DE MONTUSSAN is a French company founded 32 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in MONTUSSAN (33450), this company of category PME shows in 2025 a net income positive of 228 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE DE MONTUSSAN (SIREN 395156821)
Indicator 2025 2024 2023 2022 2022
Revenue N/C N/C N/C N/C N/C
Net income 227 946 € 187 084 € 134 457 € 156 087 € 75 657 €
EBITDA N/C N/C N/C N/C N/C
Net margin N/C N/C N/C N/C N/C

Revenue and income statement

In 2025, PHARMACIE DE MONTUSSAN generates positive net income of 228 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2022-2025: 76 k€ -> 228 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

227 946 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 101%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 39%. The balance between equity and debt is satisfactory.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

101.127%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

38.933%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

9.1%

Solvency indicators evolution
PHARMACIE DE MONTUSSAN

Sector positioning

Debt ratio
101.13 2025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Average -7 pts over 3 years

In 2025, the debt ratio of PHARMACIE DE MONTUSSAN (101.13) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
38.93% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Average +7 pts over 3 years

In 2025, the financial autonomy of PHARMACIE DE MONTUSSAN (38.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 198.38. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

198.381

Liquidity indicators evolution
PHARMACIE DE MONTUSSAN

Sector positioning

Liquidity ratio
198.38 2025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Good +19 pts over 3 years

In 2025, the liquidity ratio of PHARMACIE DE MONTUSSAN (198.38) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 225 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 817 days. Excellent situation: suppliers finance 592 days of the operating cycle (retail model).

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

225 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

817 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE DE MONTUSSAN

Positioning of PHARMACIE DE MONTUSSAN in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of PHARMACIE DE MONTUSSAN is estimated at 3 620 949 € (range 2 457 193€ - 5 681 768€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
2457k€ 3620k€ 5681k€
3 620 949 € Range: 2 457 193€ - 5 681 768€
NAF 5 année 2025

Valuation method used

Net Income Multiple
227 946 € × 15.9x = 3 620 949 €
Range: 2 457 193€ - 5 681 768€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE DE MONTUSSAN with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE DE MONTUSSAN

What is the revenue of PHARMACIE DE MONTUSSAN ?

The revenue of PHARMACIE DE MONTUSSAN is not publicly disclosed (confidential accounts filed with INPI).

Is PHARMACIE DE MONTUSSAN profitable?

Yes, PHARMACIE DE MONTUSSAN generated a net profit of 228 k€ in 2025.

Where is the headquarters of PHARMACIE DE MONTUSSAN ?

The headquarters of PHARMACIE DE MONTUSSAN is located in MONTUSSAN (33450), in the department Gironde.

Where to find the tax return of PHARMACIE DE MONTUSSAN ?

The tax return of PHARMACIE DE MONTUSSAN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE DE MONTUSSAN operate?

PHARMACIE DE MONTUSSAN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.